David Abrams Nuvation Bio Inc. Transaction History
Abrams Capital Management, L.P.
- $3.25 Billion
- Q3 2025
A detailed history of David Abrams (Abrams Capital Management, L.P.) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Abrams Capital Management, L.P. holds 3,811,513 shares of NUVB stock, worth $18.5 Million. This represents 0.43% of its overall portfolio holdings.
Number of Shares
3,811,513
Previous 3,811,513
-0.0%
Holding current value
$18.5 Million
Previous $7.43 Million
89.75%
% of portfolio
0.43%
Previous 0.24%
Shares
1 transactions
Others Institutions Holding NUVB
# of Institutions
217Shares Held
165MCall Options Held
1.99MPut Options Held
660K-
Decheng Capital LLC Menlo Park, CA26MShares$126 Million16.75% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$78.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$75.1 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY9.71MShares$47.2 Million0.67% of portfolio
-
Omega Fund Management, LLC Boston, MA8.83MShares$42.9 Million89.01% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $1.06B
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...